Cytokinetics Quarterly Income Statements Chart
Quarterly
|
Annual
Cytokinetics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-09-30 | 2011-08-05 | 2011-08-05 | 2010-08-05 | 2010-08-05 | 2009-08-05 | 2009-08-05 | 2008-08-05 | 2008-08-05 | 2007-08-05 | 2007-08-05 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-08-05 | 2006-08-05 | 2006-06-30 | 2006-03-31 | 2005-09-30 | 2005-08-05 | 2005-08-05 | 2004-09-30 | 2004-08-05 | 2004-06-30 | 2004-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| collaboration revenues | 2,416,000 | 1,579,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| license and milestone revenues | 64,353,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total revenues | 66,769,000 | 16,927,000 | 463,000 | 249,000 | 835,000 | 1,672,000 | 378,000 | 867,000 | 4,613,000 | 1,957,000 | 2,515,000 | 88,968,000 | 1,148,000 | 55,600,000 | 5,437,000 | 2,843,000 | 6,548,000 | 6,722,000 | 41,688,000 | 3,593,000 | 3,825,000 | 5,212,000 | 6,055,000 | 7,137,000 | 8,464,000 | 9,377,000 | 10,641,000 | 6,215,000 | 5,268,000 | -18,000 | 6,180,000 | 3,053,000 | 4,153,000 | 33,138,000 | 59,047,000 | 5,802,000 | 8,421,000 | 9,757,000 | 7,945,000 | 6,542,000 | 4,414,000 | 21,758,000 | 9,415,000 | 7,788,000 | 7,979,000 | 24,349,000 | 4,469,000 | 1,009,000 | 821,000 | 172,260,000 | 1,714,000 | 1,841,000 | 1,820,000 | 1,427,000 | 167,893,000 | 167,893,000 | 164,121,000 | 164,121,000 | 85,040,000 | 85,040,000 | 75,685,000 | 75,685,000 | 59,126,000 | 59,126,000 | 62,302,000 | 59,126,000 | 52,949,000 | 55,765,000 | 55,659,000 | 55,659,000 | 55,659,000 | 1,420,000 | 1,855,000 | 48,794,000 | 48,794,000 | 2,449,000 | 725,000 | 2,900,000 | 5,867,000 | |
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 112,554,000 | 99,841,000 | 93,629,000 | 84,612,000 | 79,597,000 | 81,570,000 | 84,976,000 | 82,532,000 | 83,194,000 | 79,421,000 | 75,018,000 | 62,734,000 | 57,126,000 | 45,935,000 | 43,498,000 | 48,436,000 | 36,443,000 | 31,561,000 | 29,221,000 | 24,202,000 | 21,790,000 | 21,738,000 | 18,334,000 | 20,229,000 | 24,017,000 | 23,545,000 | 23,277,000 | 21,391,000 | 21,582,000 | 22,135,000 | 26,251,000 | 24,947,000 | 19,809,000 | 19,289,000 | 17,301,000 | 19,340,000 | 9,723,000 | 13,534,000 | 13,249,000 | 11,557,000 | 12,636,000 | 8,956,000 | 8,779,000 | 11,420,000 | 11,737,000 | 12,490,000 | 13,824,000 | 13,445,000 | 12,347,000 | 9,834,000 | 462,330,000 | 8,798,000 | 8,242,000 | 8,745,000 | 8,891,000 | 434,982,000 | 434,982,000 | 386,346,000 | 386,346,000 | 347,397,000 | 347,397,000 | 312,449,000 | 312,449,000 | 242,587,000 | 242,587,000 | 256,313,000 | 242,587,000 | 193,901,000 | 217,074,000 | 204,539,000 | 204,539,000 | 204,539,000 | 11,266,000 | 9,259,000 | 160,880,000 | 160,880,000 | 9,535,000 | 130,555,000 | 9,749,000 | 9,360,000 |
| general and administrative | 65,721,000 | 57,369,000 | 62,338,000 | 56,652,000 | 50,824,000 | 45,500,000 | 44,114,000 | 40,111,000 | 39,722,000 | 49,665,000 | 53,969,000 | 48,222,000 | 42,716,000 | 33,070,000 | 33,806,000 | 26,202,000 | 21,197,000 | 15,598,000 | 13,908,000 | 12,302,000 | 14,161,000 | 12,449,000 | 10,584,000 | 9,753,000 | 9,836,000 | 9,437,000 | 7,558,000 | 7,164,000 | 8,046,000 | 9,264,000 | 10,258,000 | 9,657,000 | 8,438,000 | 8,115,000 | 6,674,000 | 7,217,000 | 7,090,000 | 6,841,000 | 5,529,000 | 5,276,000 | 4,495,000 | 4,367,000 | 4,558,000 | 3,993,000 | 4,458,000 | 4,259,000 | 4,093,000 | 3,635,000 | 3,730,000 | 3,634,000 | 147,767,000 | 2,991,000 | 2,568,000 | 3,056,000 | 3,204,000 | 137,886,000 | 137,886,000 | 119,999,000 | 119,999,000 | 104,556,000 | 104,556,000 | 93,869,000 | 93,869,000 | 73,223,000 | 73,223,000 | 77,237,000 | 73,223,000 | 57,609,000 | 64,631,000 | 61,059,000 | 61,059,000 | 61,059,000 | 3,622,000 | 3,325,000 | 47,071,000 | 47,071,000 | 3,569,000 | 37,853,000 | 2,672,000 | 2,475,000 |
| total operating expenses | 178,275,000 | 157,210,000 | 155,967,000 | 141,264,000 | 130,421,000 | 127,070,000 | 129,090,000 | 122,643,000 | 122,916,000 | 129,086,000 | 128,987,000 | 110,956,000 | 99,842,000 | 79,005,000 | 77,304,000 | 74,638,000 | 57,640,000 | 47,159,000 | 43,129,000 | 36,504,000 | 35,951,000 | 34,187,000 | 28,918,000 | 29,982,000 | 33,853,000 | 32,982,000 | 30,835,000 | 28,555,000 | 29,628,000 | 31,399,000 | 36,509,000 | 34,604,000 | 28,247,000 | 27,404,000 | 23,975,000 | 26,557,000 | 16,813,000 | 20,375,000 | 18,778,000 | 16,833,000 | 17,131,000 | 13,323,000 | 13,337,000 | 15,413,000 | 16,195,000 | 16,749,000 | 17,917,000 | 17,080,000 | 16,077,000 | 13,468,000 | 613,739,000 | 11,787,000 | 10,797,000 | 11,760,000 | 12,095,000 | 575,318,000 | 575,318,000 | 508,795,000 | 508,795,000 | 454,369,000 | 454,369,000 | 406,318,000 | 406,318,000 | 315,810,000 | 315,810,000 | 333,550,000 | 315,810,000 | 251,510,000 | 281,705,000 | 265,598,000 | 265,598,000 | 265,598,000 | 14,888,000 | 12,584,000 | 207,951,000 | 207,951,000 | 13,104,000 | 3,105,250 | 12,421,000 | 11,835,000 |
| operating income | -111,506,000 | -155,631,000 | -139,040,000 | -140,801,000 | -130,172,000 | -126,235,000 | -127,418,000 | -122,265,000 | -122,049,000 | -124,473,000 | -127,030,000 | -108,441,000 | -10,874,000 | -77,857,000 | -21,704,000 | -69,201,000 | -54,797,000 | -40,611,000 | -36,407,000 | 5,184,000 | -32,358,000 | -30,362,000 | -23,706,000 | -23,927,000 | -26,716,000 | -24,518,000 | -21,458,000 | -17,914,000 | -23,413,000 | -26,131,000 | -36,527,000 | -28,424,000 | -25,194,000 | -23,251,000 | 9,163,000 | 32,490,000 | -11,011,000 | -11,954,000 | -9,021,000 | -8,888,000 | -10,589,000 | -8,909,000 | 8,421,000 | -5,998,000 | -8,407,000 | -8,770,000 | 6,432,000 | -12,611,000 | -15,068,000 | -12,647,000 | -441,479,000 | -10,073,000 | -8,956,000 | -9,940,000 | -10,668,000 | -407,425,000 | -407,425,000 | -344,674,000 | -344,674,000 | -369,329,000 | -369,329,000 | -330,633,000 | -330,633,000 | -256,684,000 | -256,684,000 | -271,248,000 | -256,684,000 | -198,561,000 | -225,940,000 | -209,939,000 | -209,939,000 | -209,939,000 | -13,468,000 | -10,729,000 | -159,157,000 | -159,157,000 | -10,655,000 | -127,427,000 | -9,521,000 | -5,968,000 |
| yoy | -14.34% | 23.29% | 9.12% | 15.16% | 6.66% | 1.42% | 0.31% | 12.75% | 1022.39% | 59.87% | 485.28% | 56.70% | -80.16% | 91.71% | -40.39% | -1434.90% | 69.35% | 33.76% | 53.58% | -121.67% | 21.12% | 23.84% | 10.48% | 33.57% | 14.11% | -6.17% | -41.25% | -36.98% | -7.07% | 12.39% | -498.64% | -187.49% | 128.81% | 94.50% | -201.57% | -465.55% | 3.99% | 34.18% | -207.13% | 48.18% | 25.95% | 1.58% | 30.92% | -52.44% | -44.21% | -30.66% | -101.46% | 25.20% | 68.24% | 27.23% | 4038.35% | -97.53% | -97.80% | -97.12% | -96.90% | 10.31% | 10.31% | 4.25% | 4.25% | 43.88% | 43.88% | 28.81% | 28.81% | 13.61% | 13.61% | 29.20% | 22.27% | -5.42% | 1577.61% | 31.91% | 31.91% | 31.91% | 26.40% | -91.58% | 2566.84% | 2566.84% | ||||
| qoq | -28.35% | 11.93% | -1.25% | 8.17% | 3.12% | -0.93% | 4.21% | 0.18% | -1.95% | -2.01% | 17.14% | 897.25% | -86.03% | 258.72% | -68.64% | 26.29% | 34.93% | 11.55% | -802.30% | -116.02% | 6.57% | 28.08% | -0.92% | -10.44% | 8.96% | 14.26% | 19.78% | -23.49% | -10.40% | -28.46% | 28.51% | 12.82% | 8.36% | -353.75% | -71.80% | -395.07% | -7.89% | 32.51% | 1.50% | -16.06% | 18.86% | -205.80% | -240.40% | -28.65% | -4.14% | -236.35% | -151.00% | -16.31% | 19.14% | -97.14% | 4282.80% | 12.47% | -9.90% | -6.82% | -97.38% | 18.21% | 18.21% | -6.68% | -6.68% | 11.70% | 11.70% | 28.81% | 28.81% | -5.37% | -5.37% | 5.67% | 29.27% | -12.12% | 7.62% | 0.00% | 0.00% | 1458.80% | 25.53% | -93.26% | 1393.73% | 1393.73% | -91.64% | 1238.38% | 59.53% | |
| operating margin % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense | -11,084,000 | -8,938,000 | -8,928,000 | -12,732,000 | -7,103,000 | -7,164,000 | -7,136,000 | -7,045,000 | -6,961,000 | -7,057,000 | -6,804,000 | -2,807,000 | -2,746,000 | -4,218,000 | -4,161,000 | -4,073,000 | -3,988,000 | -4,018,000 | -3,976,000 | -3,892,000 | -4,077,000 | -2,731,000 | -1,345,000 | -1,377,000 | -1,170,000 | -1,169,000 | -867,000 | -898,000 | -863,000 | -670,000 | -806,000 | -782,000 | -3,052,000 | -713,000 | -714,000 | 10.31% | 10.31% | 4.25% | 4.25% | 43.88% | 43.88% | 21.89% | 21.89% | 29.27% | 29.27% | 1856.74% | 1856.74% | 1571.64% | 1571.64% | |||||||||||||||||||||||||||||||
| non-cash interest expense on liabilities related to revenue participation right purchase agreements | -13,181,000 | -14,078,000 | -13,656,000 | -13,370,000 | -11,567,000 | -10,218,000 | -9,900,000 | -6,860,000 | -6,322,000 | -6,280,000 | -9,212,000 | -8,963,000 | -7,003,000 | -6,564,000 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest and other income | 13,001,000 | -8,868,000 | 15,014,000 | 17,054,000 | 11,553,000 | 7,913,000 | 7,586,000 | 6,839,000 | 6,779,000 | 6,425,000 | 5,919,000 | 4,144,000 | 864,000 | 415,000 | -377,000 | 231,000 | 187,000 | 290,000 | 2,146,000 | 1,078,000 | 1,382,000 | 723,000 | 1,330,000 | 1,020,000 | 900,000 | 1,323,000 | 1,126,000 | 842,000 | 774,000 | 779,000 | 612,000 | 436,000 | 182,000 | 111,000 | -600,000 | -501,000 | 20,815,000 | 18,693,000 | 12,879,000 | 15,278,000 | 14,063,000 | 1,128,000 | 756,000 | 983,000 | 8,009,000 | 780,000 | 519,000 | |||||||||||||||||||||||||||||||||
| change in fair value of derivative liabilities | 3,000,000 | -400,000 | 1,200,000 | 700,000 | -600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| change in fair value of liabilities related to rpi transactions | -14,600,000 | 3,900,000 | -4,600,000 | -15,200,000 | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income | -134,370,000 | -161,376,000 | -150,020,000 | -160,545,000 | -143,318,000 | -135,643,000 | -136,896,000 | -129,422,000 | -128,637,000 | -131,289,000 | -137,380,000 | -142,310,000 | -19,820,000 | -89,445,000 | -30,570,000 | -76,086,000 | -61,554,000 | -47,104,000 | -43,930,000 | -3,175,000 | -40,780,000 | -39,405,000 | -30,640,000 | -29,573,000 | -32,113,000 | -29,366,000 | -26,468,000 | -22,017,000 | -27,523,000 | -30,281,000 | -40,485,000 | -32,357,000 | -29,081,000 | -25,867,000 | 8,632,000 | 31,887,000 | -11,611,000 | -12,455,000 | -9,229,000 | -8,849,000 | -10,551,000 | -8,872,000 | 8,443,000 | -5,971,000 | -8,374,000 | -8,744,000 | 6,531,000 | -12,588,000 | -15,041,000 | -12,619,000 | -419,966,000 | -10,044,000 | -8,943,000 | -9,928,000 | -10,639,000 | 26,992,000 | 26,992,000 | 18,693,000 | 18,693,000 | -254,959,000 | -242,331,000 | -189,470,000 | -214,693,000 | 14,063,000 | 14,063,000 | -199,773,000 | -12,464,000 | -10,101,000 | 10,190,000 | 10,190,000 | -10,216,000 | -122,041,000 | -9,231,000 | -5,932,000 | ||||||
| yoy | -6.24% | 18.97% | 9.59% | 24.05% | 11.41% | 3.32% | -0.35% | -9.06% | 549.03% | 46.78% | 349.39% | 87.04% | -67.80% | 89.89% | -30.41% | 2296.41% | 50.94% | 19.54% | 43.37% | -89.26% | 26.99% | 34.19% | 15.76% | 34.32% | 16.68% | -3.02% | -34.62% | -31.96% | -5.36% | 17.06% | -569.01% | -201.47% | 150.46% | 107.68% | -193.53% | -460.35% | 10.05% | 40.39% | -209.31% | 48.20% | 26.00% | 1.46% | 29.28% | -52.57% | -44.33% | -30.71% | -101.56% | 25.33% | 68.19% | 27.11% | 3847.42% | -97.40% | -97.68% | -96.93% | -96.71% | 11.37% | 11.37% | 4.78% | 4.78% | 43.02% | 43.02% | 27.43% | 27.43% | 12.87% | 12.87% | 27.62% | 21.30% | -5.16% | 1622.50% | 31.13% | 31.13% | 31.13% | 22.00% | -91.72% | 2468.14% | 2468.14% | ||||
| qoq | -16.73% | 7.57% | -6.56% | 12.02% | 5.66% | -0.92% | 5.77% | 0.61% | -2.02% | -4.43% | -3.46% | 618.01% | -77.84% | 192.59% | -59.82% | 23.61% | 30.68% | 7.23% | 1283.62% | -92.21% | 3.49% | 28.61% | 3.61% | -7.91% | 9.35% | 10.95% | 20.22% | -20.01% | -9.11% | -25.20% | 25.12% | 11.27% | 12.43% | -399.66% | -72.93% | -374.63% | -6.78% | 34.96% | 4.29% | -16.13% | 18.92% | -205.08% | -241.40% | -28.70% | -4.23% | -233.88% | -151.88% | -16.31% | 19.19% | -97.00% | 4081.26% | 12.31% | -9.92% | -6.68% | -97.24% | 19.30% | 19.30% | -6.65% | -6.65% | 12.24% | 12.24% | 27.43% | 27.43% | -4.95% | -4.95% | 5.21% | 27.90% | -11.75% | 7.47% | 0.00% | 0.00% | 1502.80% | 23.39% | -93.37% | 1391.21% | 1391.21% | -91.63% | 1222.08% | 55.61% | |
| net income margin % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | -1.12 | -1.36 | -1.26 | -1.36 | -1.31 | -1.33 | -1.38 | -1.35 | -1.34 | -1.38 | -1.48 | -1.52 | -0.23 | -1.05 | -0.32 | -0.95 | -0.86 | -0.66 | -0.63 | -0.05 | -0.68 | -0.66 | -0.51 | -0.5 | -0.56 | -0.54 | -0.368 | -0.4 | -0.51 | -0.56 | -0.77 | -0.6 | -0.6 | -0.62 | 0.21 | 0.8 | -0.29 | -0.31 | -0.24 | -0.23 | -0.27 | -0.23 | 0.24 | -0.16 | -0.23 | -0.27 | 0.28 | -0.43 | -0.58 | -0.09 | -0.078 | -0.07 | -0.13 | -0.13 | -0.15 | |||||||||||||||||||||||||
| weighted-average number of shares used in computing net income per share — basic and diluted | 119,457 | 118,496 | 111,979 | 117,685 | 109,240 | 101,924 | 96,524 | 96,071 | 95,755 | 95,164 | 89,825 | 93,758 | 85,731 | 84,996 | 76,886 | 80,329 | 71,754 | 71,195 | 64,524 | 68,279 | 59,605 | 59,270 | 57,575 | 54,420 | 48,218 | 41,578 | 39,666 | 39,592 | 38,814 | 38,752 | 38,725 | 38,675 | 36,609 | 36,443 | 32,985 | |||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive gain: | -385,994,000 | -385,994,000 | -323,552,000 | -323,552,000 | -346,592,000 | -346,592,000 | -308,791,000 | -308,791,000 | -242,331,000 | -242,331,000 | -199,773,000 | -199,773,000 | -152,342,000 | -152,342,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities | -851 | -541 | 1,969 | -1,065 | -905 | -2,720 | 11.37% | 11.37% | 4.78% | 4.78% | 43.02% | 43.02% | 21.11% | 21.11% | 27.90% | 27.90% | 1877.75% | 1877.75% | 1550.33% | 1550.33% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| foreign currency translation adjustments | -852 | -312 | 338 | -126 | 16 | 27 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| comprehensive loss | -136,073 | -162,229 | -153,009 | -154,136 | -143,801 | -136,172 | -136,032 | -128,838 | -128,450 | -129,344 | -135,411 | -143,375 | -20,725 | -92,165 | -31,374 | -76,129 | -61,626 | -47,203 | -44,739 | -3,554 | -41,056 | -38,471 | -30,680 | -29,615 | -31,958 | -29,260 | -26,415 | -22,014 | -27,562 | -30,135 | -29,159 | -26,012 | -11,538 | -12,448 | -9,095 | -8,847 | -10,533 | -8,873 | 8,415 | -5,960 | -8,374 | -8,738 | 6,519 | -12,569 | -15,051 | -12,627 | -419,958 | -10,030 | -8,942 | -9,933 | ||||||||||||||||||||||||||||||
| research and development revenues | 386,750 | 463,000 | 249,000 | 835,000 | 672,000 | 378,000 | 867,000 | 2,113,000 | 1,957,000 | 2,515,000 | 968,000 | 1,148,000 | 744,000 | 437,000 | 2,843,000 | 6,548,000 | 3,922,000 | 5,187,000 | 3,593,000 | 3,825,000 | 5,212,000 | 6,055,000 | 7,137,000 | 8,464,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| milestone revenues | 1,000,000 | 2,500,000 | 1,000,000 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities | -3,327 | 6,535 | 884 | 584 | 187 | 1,945 | -804 | -43 | -72 | -99 | 69.75 | -379 | -276 | 934 | 54.75 | -42 | 155 | 106 | 26 | 3 | -39 | 146 | 72.25 | 512 | -78 | -145 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized (loss)/gain on available-for-sale securities | -499 | -556 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| realization of revenue participation right purchase agreement | 87,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -2,693,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive income: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive loss: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on settlement of debt | -22,246,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| license revenues | 36,501,000 | 1,915,000 | 1,535,000 | 1,683,000 | 2,093,000 | 318,000 | 4,942,000 | 2,271,000 | 2,734,000 | 2,749,000 | 2,082,000 | 2,442,000 | 1,410,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| non-cash interest expense on liability related to the sale of future royalties | -2,155,250 | -2,955,000 | -2,871,000 | -2,795,000 | -4,265,500 | -5,461,000 | -5,912,000 | -5,689,000 | -3,801,000 | -5,321,000 | -5,064,000 | -4,819,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average shares in net income per share — basic and diluted | 58,640 | 57,648 | 54,821 | 54,626 | 54,293 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income | 1,044,000 | 1,141,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development, milestone, grant and other revenues | 4,247,750 | 8,726,000 | 4,680,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| non-cash interest expense on liability related to sale of future royalties | -4,741,000 | -4,559,000 | -4,338,000 | -4,129,000 | -4,062,000 | -3,906,000 | -3,717,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development, grant and other revenues | 3,585,000 | -2,111,000 | 5,862,000 | -1,889,000 | 341,000 | 312,000 | 441,000 | 337,000 | 151,000 | 48,000 | 27,000 | 3,377,000 | 4,761,000 | 4,196,000 | 5,232,000 | 4,113,000 | 2,495,000 | 446,000 | 493,000 | 7,231,000 | 751,000 | 746,000 | 644,000 | 433,000 | 2,955,000 | 2,955,000 | 2,951,000 | 2,955,000 | 2,955,000 | 2,000 | 300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average shares used for eps calculation | 54,062 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income before income taxes | -21,826,250 | -32,357,000 | -25,867,000 | 1,955,250 | 31,887,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares used in computing net income per share — basic | 49,404 | 53,719 | 39,943 | 39,926 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares used in computing net income per share — diluted | 49,404 | 53,719 | 42,561 | 43,217 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| comprehensive income | -40,568 | -31,845 | 8,517 | 31,910 | 4,818,000 | 4,818,000 | 2,955,000 | 2,955,000 | 2,955,000 | 2,955,000 | 2,955,000 | 2,955,000 | 2,955,000 | 2,955,000 | 2,955,000 | 2,955,000 | 2,425,000 | 2,425,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development revenues from related parties | 2,366,000 | 29,611,000 | 5,573,000 | 3,515,000 | 4,296,000 | 4,578,000 | 3,786,000 | 3,510,000 | 2,791,000 | 16,110,000 | 1,920,000 | 843,000 | 665,000 | 564,000 | 564,000 | 563,000 | 328,000 | 52,094,000 | 963,000 | 1,095,000 | 1,176,000 | 994,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| license revenues from related parties | 1,446,000 | 3,215,000 | 53,033,000 | 1,950,000 | 3,974,000 | 5,131,000 | 4,132,000 | 3,032,000 | 1,623,000 | 20,217,000 | 17,159,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gains on available-for-sale securities | -115 | 23 | 73 | 7 | 134 | 2 | 18 | -1 | -28 | 11 | 6 | -26,000 | -26,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income taxes | -11,611,000 | -12,455,000 | -9,229,000 | -8,849,000 | -10,551,000 | -8,872,000 | 8,443,000 | -5,971,000 | -8,374,000 | -8,744,000 | 6,531,000 | -12,588,000 | -15,041,000 | -12,619,000 | -419,992,000 | -10,044,000 | -8,943,000 | -9,928,000 | -10,639,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest and other | 28,500 | 39,000 | 38,000 | 37,000 | 22,000 | 27,000 | 33,000 | 26,000 | 99,000 | 23,000 | 27,000 | 28,000 | 21,487,000 | 29,000 | 13,000 | 12,000 | 29,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| restructuring charges | 3,642,000 | -2,000 | -13,000 | -41,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| deemed dividend related to beneficial conversion feature of convertible preferred stock | -2,857,000 | -1,307,000 | 50,140,000 | 50,140,000 | 48,231,000 | 48,231,000 | 40,459,000 | 40,459,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income allocable to common stockholders | 6,531,000 | -12,588,000 | -15,041,000 | -12,619,000 | -422,823,000 | -10,044,000 | -10,250,000 | -9,928,000 | -10,639,000 | 112,935,000 | 112,935,000 | 112,935,000 | 112,935,000 | 41,626,000 | 41,626,000 | 32,451,000 | 32,451,000 | 17,159,000 | 17,159,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares used in computing net income per share allocable to common stockholders — basic and diluted | 35,709 | 27,275 | 29,395 | 25,773 | 144,061 | 134,162 | 81,230 | 72,280 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares used in computing net income per common share — basic and diluted | 76,082 | -386,020,000 | -386,020,000 | -323,402,000 | -323,402,000 | 34,247,000 | 28,589,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit from income taxes | 21,405,000 | 21,405,000 | 21,272,000 | 21,272,000 | 22,737,000 | 22,737,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share — basic and diluted | 2,450,000 | 2,450,000 | 2,450,000 | 2,450,000 | 2,416,000 | 2,416,000 | -287.5 | -360 | -350 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development revenues from related party | -2,857,000 | -2,857,000 | 39,130,000 | 39,012,000 | 37,297,000 | 38,810,000 | 38,704,000 | 718,000 | 855,000 | 1,449,000 | 30,370,000 | 1,895,000 | 5,067,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| includes the following stock-based compensation charges: | -388,851,000 | -388,851,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| license revenues from related party | 350,000 | 14,000,000 | 14,000,000 | 700,000 | 700,000 | 700,000 | 9,100,000 | 700,000 | 700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development and grant revenues | 300,000 | 76,250 | 305,000 | 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | -1.12 | -1.36 | -1.26 | -1.36 | -1.31 | -1.33 | -1.38 | -1.35 | -1.34 | -1.38 | -1.48 | -1.52 | -0.23 | -1.05 | -0.32 | -0.95 | -0.86 | -0.66 | -0.63 | -0.05 | -0.68 | -0.66 | -0.51 | -0.5 | -0.56 | -0.54 | -0.368 | -0.4 | -0.51 | -0.56 | -0.77 | -0.6 | -0.6 | -0.62 | 0.21 | 0.8 | -0.29 | -0.31 | -0.24 | -0.23 | -0.27 | -0.23 | 0.24 | -0.16 | -0.23 | -0.27 | 0.28 | -0.43 | -0.58 | -0.09 | -0.078 | -0.07 | -0.13 | -0.13 | -0.15 | 150,000 | 150,000 | |||||||||||||||||||||||
| basic and diluted | -0.36 | -0.115 | -0.46 | -2.56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares used in per share calculations: | 40,279,000 | 40,279,000 | 39,012,000 | 39,012,000 | 38,704,000 | 38,704,000 | 35,169,000 | 35,169,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | 28,154,119 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| includes the following stock based compensation charges: | 14,000,000 | 14,000,000 | 11,200,000 | 11,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted- average number of shares used in per share calculations: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | 19,905 | 2,313 |
We provide you with 20 years income statements for Cytokinetics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cytokinetics stock. Explore the full financial landscape of Cytokinetics stock with our expertly curated income statements.
The information provided in this report about Cytokinetics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.